| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01567540 2011-000823-34 Details | 2014-01-20 Interventional | 1 | 3 | Sitagliptin Pho… Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… | New treatments available, which prevents additional recruitment. - | |||
| NCT00095693 Details | 2014-01-16 Interventional | 2 | 25 | Fluorodeoxygluc… Sorafenib Adenocarcinoma,… Thyroid Cancer,… Thyroid Carcino… Thyroid Disease… Thyroid Neoplas… Anaplastic Thyr… Insular Thyroid… Recurrent Thyro… Stage III Folli… Stage III Papil… Stage IV Follic… Stage IV Papill… | - - | |||
| NCT01708057 2012-002900-42 Details | 2014-01-15 Interventional | 2 | 3 | Tiotropium Brom… Lung Diseases Lung Diseases, … Pulmonary Disea… COPD Chronic Obstruc… | - - | |||
| NCT01818648 Details | 2014-01-14 Interventional | 4 | 0 | Exenatide Short Bowel Syn… Syndrome | Study was withdrawn by PI due to decision to study a different medication. - | |||
| NCT00922129 Details | 2014-01-14 Interventional | 2/3 | 0 | Cyclosporine Cyclosporins MTOR Inhibitors Sirolimus Tacrolimus Temsirolimus Prostatic Neopl… Prostate Cancer | Study did not start up as planned. - | |||
| NCT00819754 Details | 2014-01-14 Interventional | 1/2 | 23 | Bevacizumab Capecitabine Irinotecan Oxaliplatin Colorectal Neop… Metastatic Colo… | - - | |||
| NCT00417768 Details | 2014-01-14 Interventional | 2/3 | 35 | Plasminogen Tissue Plasmino… Abscess | Change in patient population no longer fit study criteria. - | |||
| NCT00337376 Details | 2014-01-14 Interventional | 1 | 23 | Albumin-Bound P… Paclitaxel Sirolimus Advanced Solid … | - - | |||
| NCT00077948 Details | 2014-01-10 Interventional | 3 | - | Enoximone Metoprolol Heart Failure Heart Failure, … | - - | |||
| NCT00051285 Details | 2014-01-10 Interventional | 3 | - | Enoximone Heart Failure Heart Failure, … | - - | |||
| NCT01363310 Details | 2014-01-08 Interventional | 3 | - | Escitalopram Quetiapine Fuma… Depression Depressive Diso… Depression With… | Termination of sponsorship - | |||
| NCT01065051 Details | 2014-01-06 Interventional | 2 | 1 | Riociguat Hypertension Hypertension, P… Ventricular Dys… Ventricular Dys… | - The study was terminated prematurely due to low recruitment (one subject enrolled only). No statistical analyses of efficacy parameters were performed. Therefore, no clinically meaningful conclusions can be drawn from the data generated. | |||
| NCT00613730 Details | 2014-01-06 Interventional | 2 | 3 | Gemcitabine Panitumumab Adenocarcinoma Pancreatic Neop… Cancer of Pancr… Cancer of the P… Pancreas Cancer Pancreatic Canc… | APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE
enrollment closure due to similar design;no unexpected safety data - | |||
| NCT00389675 Details | 2014-01-06 Interventional | 3 | 661 | Darusentan Guanfacine Hypertension | Study DAR-312 did not meet its primary co-endpoints. - | |||
| NCT00203047 Details | 2014-01-06 Interventional | 4 | [1 Refs] | 414 | (T,G)-A-L Glatiramer Acet… Prednisone Multiple Sclero… Multiple Sclero… Sclerosis Relapsing Remit… | Slow enrollment decreased sample size; No unexpected safety issues. - | ||
| NCT01871480 Details | 2013-12-30 Interventional | 2 | - | Gefitinib Adenocarcinoma Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | - - | |||
| NCT01134627 NCT00381459 2005-004289-18 Details | 2013-12-27 Interventional | 2 | 305 | Minocycline Multiple Sclero… Multiple Sclero… Sclerosis | - - | |||
| NCT01071200 NCT00267761 2004-002218-13 Details | 2013-12-27 Interventional | 3 | 133 | Follicle Stimul… Hormones Infertility Reproductive Te… | - - | |||
| NCT00646763 Details | 2013-12-20 Interventional | 2 | 35 | Lenograstim Mitogens Sargramostim Cytokines | Accrual goal met - | |||
| NCT00923234 Details | 2013-12-18 Interventional | 1 | - | Azacitidine Lenalidomide Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome Acute Myelogeno… | The primary objective has already been answered with the number of recruited patients. - |